Oyster Point Pharma welcomes addition of Dr. George Eliades to its Board of Directors

– USA, NJ –  Oyster Point Pharma, Inc. (NASDAQ: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the addition of Dr. George Eliades, Ph.D. to its Board of Directors, effective immediately.

Dr. George Eliades, current SVP, Corporate Development, and Chief Transformation Officer of Jazz Pharmaceuticals (Nasdaq: JAZZ), will join the Board and serve as a member of the Compensation Committee.

“We are excited to welcome George to our Board of Directors as we build the commercial infrastructure of Oyster Point Pharma,” said CEO, Dr. Jeff Nau. “George has extensive experience developing global sales and marketing strategies for numerous therapies in biotech and pharma, and we look forward to his insights and contributions as we work to bring transformative therapies to patients with ocular surface diseases.”

About Dr. George Eliades

Dr. George Eliades has served as SVP, Corporate Development, and Chief Transformation Officer of Jazz Pharmaceuticals, a global biopharmaceutical company, since December 2020. From November 2007 to December 2020, Dr. Eliades was a partner at Bain & Company, where he focused primarily on advising biopharmaceutical clients. Dr. Eliades has advised multiple clients on their transformation agendas, including strategy, cost, M&A, and digital-driven transformation.

“I look forward to helping Oyster Point Pharma transform from a development company to a high-growth commercial organization that has the potential to address unmet needs in the ocular surface disease area for both patients and eye care professionals,” said Dr. Eliades. “I look forward to being part of Oyster Point Pharma’s growth as the company prepares for the potential launch of OC-01 nasal spray and working closely with Jeff and the rest of the Board.”

About Oyster Point Pharma

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01 nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit. OC-01 nasal spray is an investigational new drug and has not been approved for any use in any country. The safety and efficacy of OC-01 nasal spray have not previously been established.

For more information: https://oysterpointrx.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team